Viracta Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Viracta Therapeutics

08/05/2023 23:22

* Viracta Therapeutics Inc  VIRX.OQ  reported a quarterly
adjusted
loss of 32 cents​​ per share for the quarter ended in March. The
mean expectation of four analysts for the quarter was for a loss
of 31 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Viracta Therapeutics Inc's reported EPS for the quarter
was a
loss of 32 cents​.
    * The mean earnings estimate of analysts had risen by
about 8.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Viracta Therapeutics Inc shares had fallen by 37.1% this
quarter and lost 31.5% so far this year.
    * The company reported a quarterly loss of $12.12 million.
    * Wall Street's median 12-month price target for Viracta
Therapeutics Inc is $11.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
8 at 10:21 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.31          -0.32          Missed
 Dec. 31 2022      -0.38          -0.27          Beat
 Sep. 30 2022      -0.30          -0.47          Missed
 Jun. 30 2022      -0.30          -0.28          Beat